COVID-19 Vaccine Enters Phase III Trial
NIAID and Moderna announced that their jointly developed experimental vaccine officially began its much-anticipated phase III clinical trial. The potential vaccine is the first in the United States to enter a large-scale trial. This phase of testing will include 30,000 adults. In order to demonstrate its effectiveness, the vaccine will have to provide protection for 60% of study participants. The public-private partnership between the US government and Moderna aims to produce “hundreds of millions” of doses by early next year.
Full Story: Science Speaks